CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Trade Regeneron Pharmaceuticals, Inc. - REGN CFD

724.16
0.08%
0.96
Low: 719.4
High: 724.25
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.96
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.025457%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.003235%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Regeneron Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 724.73
Open* 719.68
1-Year Change* 4.13%
Day's Range* 719.4 - 724.25
52 wk Range 538.01-837.55
Average Volume (10 days) 526.40K
Average Volume (3 months) 12.32M
Market Cap 79.55B
P/E Ratio 19.70
Shares Outstanding 109.71M
Revenue 12.37B
EPS 36.80
Dividend (Yield %) N/A
Beta 0.23
Next Earnings Date Aug 1, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
May 26, 2023 724.16 6.53 0.91% 717.63 725.78 714.89
May 25, 2023 724.73 -1.54 -0.21% 726.27 735.68 720.88
May 24, 2023 736.33 -8.07 -1.08% 744.40 749.62 733.81
May 23, 2023 748.25 2.25 0.30% 746.00 756.01 742.38
May 22, 2023 751.11 -2.46 -0.33% 753.57 767.37 741.84
May 19, 2023 758.77 8.95 1.19% 749.82 763.46 748.95
May 18, 2023 746.56 7.53 1.02% 739.03 748.87 738.93
May 17, 2023 749.39 12.94 1.76% 736.45 750.67 731.31
May 16, 2023 741.89 -1.04 -0.14% 742.93 745.74 737.76
May 15, 2023 750.02 7.19 0.97% 742.83 751.68 737.22
May 12, 2023 743.62 -2.36 -0.32% 745.98 751.60 738.44
May 11, 2023 744.86 0.35 0.05% 744.51 748.90 739.33
May 10, 2023 748.70 0.93 0.12% 747.77 754.71 745.53
May 9, 2023 754.26 3.63 0.48% 750.63 756.40 744.25
May 8, 2023 749.96 -4.79 -0.63% 754.75 758.99 745.28
May 5, 2023 758.58 4.35 0.58% 754.23 768.25 741.55
May 4, 2023 751.10 -18.48 -2.40% 769.58 774.09 743.44
May 3, 2023 800.80 -2.06 -0.26% 802.86 812.34 789.70
May 2, 2023 798.08 -2.45 -0.31% 800.53 814.72 795.39
May 1, 2023 805.79 6.91 0.86% 798.88 811.12 798.88

Regeneron Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Tuesday, May 30, 2023

Time (UTC)

16:30

Country

US

Event

Regeneron Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual)
Regeneron Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual)

Forecast

-

Previous

-
Wednesday, June 7, 2023

Time (UTC)

12:30

Country

US

Event

Regeneron Pharmaceuticals Inc at Jefferies Healthcare Conference
Regeneron Pharmaceuticals Inc at Jefferies Healthcare Conference

Forecast

-

Previous

-
Friday, June 9, 2023

Time (UTC)

14:30

Country

US

Event

Regeneron Pharmaceuticals Inc Annual Shareholders Meeting
Regeneron Pharmaceuticals Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, June 14, 2023

Time (UTC)

15:40

Country

US

Event

Regeneron Pharmaceuticals Inc at Goldman Sachs Healthcare Conference
Regeneron Pharmaceuticals Inc at Goldman Sachs Healthcare Conference

Forecast

-

Previous

-
Tuesday, August 1, 2023

Time (UTC)

12:30

Country

US

Event

Q2 2023 Regeneron Pharmaceuticals Inc Earnings Release
Q2 2023 Regeneron Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Wednesday, November 1, 2023

Time (UTC)

12:30

Country

US

Event

Q3 2023 Regeneron Pharmaceuticals Inc Earnings Release
Q3 2023 Regeneron Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 12172.9 16071.7 8497.1 7863.4 6710.8
Revenue 12172.9 16071.7 8497.1 7863.4 6710.8
Cost of Revenue, Total 1560.4 2437.5 1119.9 782.2 434.1
Gross Profit 10612.5 13634.2 7377.2 7081.2 6276.7
Total Operating Expense 7434 7124.9 4920.5 5653.6 4176.4
Selling/General/Admin. Expenses, Total 2115.9 1824.9 1346 1834.8 1556.2
Research & Development 3592.5 2908.1 2735 3036.6 2186.1
Operating Income 4738.9 8946.8 3576.6 2209.8 2534.4
Interest Income (Expense), Net Non-Operating -19.6 328.8 139.1 88.1 13.7
Other, Net 139.5 50.2 94.7 131.2 5.4
Net Income Before Taxes 4858.8 9325.8 3810.4 2429.1 2553.5
Net Income After Taxes 4338.4 8075.3 3513.2 2115.8 2376.4
Net Income Before Extra. Items 4338.4 8075.3 3513.2 2115.8 2376.4
Net Income 4338.4 8075.3 3513.2 2115.8 2444.4
Income Available to Common Excl. Extra. Items 4338.4 8075.3 3513.2 2115.8 2376.4
Income Available to Common Incl. Extra. Items 4338.4 8075.3 3513.2 2115.8 2444.4
Dilution Adjustment
Diluted Net Income 4338.4 8075.3 3513.2 2115.8 2444.4
Diluted Weighted Average Shares 113.5 112.2 115.1 114.6 114.8
Diluted EPS Excluding Extraordinary Items 38.2238 71.9724 30.523 18.4625 20.7003
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS 40.4714 71.9724 30.523 18.4625 20.7003
Total Extraordinary Items 68
Other Operating Expenses, Total -89.9 -45.6 -280.4
Unusual Expense (Income) 255.1
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 3162.1 3414.4 2936.2 2857.2 2965.1
Revenue 3162.1 3414.4 2936.2 2857.2 2965.1
Cost of Revenue, Total 457.5 540.6 317.8 297.1 404.9
Gross Profit 2704.6 2873.8 2618.4 2560.1 2560.2
Total Operating Expense 2215.4 2267.6 1712.5 1747.3 1706.6
Selling/General/Admin. Expenses, Total 601.1 660.5 529.1 476.3 450
Research & Development 1101.2 1043.1 911.3 794.3 843.8
Other Operating Expenses, Total -0.5 -6.6 -45.7 -17.4 -20.2
Operating Income 946.7 1146.8 1223.7 1109.9 1258.5
Interest Income (Expense), Net Non-Operating -87.5 143 239 -176.8 -224.8
Other, Net -1.2 34.9 47.1 30.1 27.4
Net Income Before Taxes 858 1324.7 1509.8 963.2 1061.1
Net Income After Taxes 817.8 1197.1 1315.7 852.1 973.5
Net Income Before Extra. Items 817.8 1197.1 1315.7 852.1 973.5
Net Income 817.8 1197.1 1315.7 852.1 973.5
Income Available to Common Excl. Extra. Items 817.8 1197.1 1315.7 852.1 973.5
Income Available to Common Incl. Extra. Items 817.8 1197.1 1315.7 852.1 973.5
Diluted Net Income 817.8 1197.1 1315.7 852.1 973.5
Diluted Weighted Average Shares 114 114.1 112.8 114 113.1
Diluted EPS Excluding Extraordinary Items 7.17368 10.4917 11.664 7.47456 8.60743
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 7.66579 10.7546 11.664 9.20263 8.85588
Unusual Expense (Income) 56.1 30 0 197 28.1
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 15884.1 14014.9 9779.1 7689.1 6447.6
Cash and Short Term Investments 7742.3 5694.7 3587 3214.3 2809.9
Cash & Equivalents 3105.9 2885.6 2193.7 1617.8 1467.7
Short Term Investments 4636.4 2809.1 1393.3 1596.5 1342.2
Total Receivables, Net 5328.7 6036.5 4114.7 2672.2 2243.2
Accounts Receivable - Trade, Net 5328.7 6036.5 4114.7 2672.2 2243.2
Total Inventory 2401.9 1951.3 1916.6 1415.5 1151.2
Prepaid Expenses 411.2 332.4 160.8 387.1 243.3
Other Current Assets, Total
Total Assets 29214.5 25434.8 17163.3 14805.2 11734.5
Property/Plant/Equipment, Total - Net 3763 3482.2 3221.6 2890.4 2575.8
Property/Plant/Equipment, Total - Gross 5432.2 4880.3 4352.7 3812.8 3304.5
Accumulated Depreciation, Total -1669.2 -1398.1 -1131.1 -922.4 -728.7
Long Term Investments 6640.1 6878 3194.8 3312.4 1800.5
Other Long Term Assets, Total 2011.8 1059.7 967.8 913.3 910.6
Total Current Liabilities 3141.3 3932.5 2697.4 2096.6 1442.8
Accounts Payable 589.2 564 475.5 418.1 218.2
Accrued Expenses 2073.9 1880.5 1502.3 1037.4 751.3
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 719.7
Other Current Liabilities, Total 478.2 768.3 719.6 641.1 473.3
Total Liabilities 6550.5 6666 6138 3715.5 2977.2
Total Long Term Debt 2701.4 1980 2695.7 713.9 708.5
Capital Lease Obligations 720 0 717.2 713.9 708.5
Other Liabilities, Total 707.8 753.5 744.9 905 825.9
Total Equity 22664 18768.8 11025.3 11089.7 8757.3
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.1 0.1 0.1 0.1 0.1
Additional Paid-In Capital 9949.3 8087.5 6716.2 4428.6 3911.6
Retained Earnings (Accumulated Deficit) 23306.7 18968.3 10893 7379.8 5254.3
Treasury Stock - Common -10353.3 -8260.9 -6613.3 -739.9 -396.4
Other Equity, Total -238.8 -26.2 29.3 21.1 -12.3
Total Liabilities & Shareholders’ Equity 29214.5 25434.8 17163.3 14805.2 11734.5
Total Common Shares Outstanding 109.6 108.675 106.951 110.277 109.006
Long Term Debt 1981.4 1980 1978.5
Intangibles, Net 915.5
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 16909.2 15884.1 15428.6 15529.9 14306
Cash and Short Term Investments 8959.7 7742.3 7021.7 7566.4 7050.6
Cash & Equivalents 3916.3 3105.9 3491.3 3395.1 3345.7
Short Term Investments 5043.4 4636.4 3530.4 4171.3 3704.9
Total Receivables, Net 5118.6 5328.7 5548.3 5161.4 4839
Accounts Receivable - Trade, Net 5118.6 5328.7 5548.3 5161.4 4839
Total Inventory 2424.7 2401.9 2412.2 2218.5 1991.5
Prepaid Expenses 406.2 411.2 446.4 583.6 424.9
Other Current Assets, Total
Total Assets 30059.9 29214.5 27677.8 27205.8 26348.7
Property/Plant/Equipment, Total - Net 3880.9 3763 3704.2 3637.7 3556.4
Long Term Investments 6114.9 6640.1 6016.9 6463.2 7130.7
Other Long Term Assets, Total 2226.2 2011.8 1724 1575 1355.6
Total Current Liabilities 3100.1 3141.3 2879.2 3033.9 3007.6
Accounts Payable 599.5 589.2 535.6 534.2 470.3
Accrued Expenses 2074.3 2074.2 1796.4 1933.4 2046
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0 0 0
Other Current Liabilities, Total 426.3 477.9 547.2 566.3 491.3
Total Liabilities 6564.7 6550.5 6239 6518 6434
Total Long Term Debt 2701.8 2701.4 2701.1 2700.7 2700.4
Long Term Debt 1981.8 1981.4 1981.1 1980.7 1980.4
Capital Lease Obligations 720 720 720 720 720
Other Liabilities, Total 762.8 707.8 658.7 783.4 726
Total Equity 23495.2 22664 21438.8 20687.8 19914.7
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0 0.1 0.1 0.1 0.1
Additional Paid-In Capital 10597.7 9949.3 9518.2 9120.2 8754.1
Retained Earnings (Accumulated Deficit) 24124.5 23306.7 22109.6 20793.9 19941.8
Treasury Stock - Common -11045.5 -10353.3 -9914 -9002.6 -8611.2
Other Equity, Total -181.5 -238.8 -275.1 -223.8 -170.1
Total Liabilities & Shareholders’ Equity 30059.9 29214.5 27677.8 27205.8 26348.7
Total Common Shares Outstanding 109.7 109.6 108.8 109.5 109.507
Intangibles, Net 928.7 915.5 804.1
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 4338.4 8075.3 3513.2 2115.8 2444.4
Cash From Operating Activities 5014.9 7081.3 2618.1 2430 2195.1
Cash From Operating Activities 341.4 286.2 235.9 210.3 148.2
Deferred Taxes -746.4 -147.1 75.6 -130.6 -140
Non-Cash Items 1324.8 783.4 297 435 439.5
Cash Taxes Paid 1502.4 1218.4 188.1 342.3 205.6
Cash Interest Paid 53.7 55.8 23.2 25 22.3
Changes in Working Capital -243.3 -1916.5 -1503.6 -200.5 -697
Cash From Investing Activities -3784.6 -5384.7 -70.6 -2027.8 -1463
Capital Expenditures -1616.9 -551.9 -614.6 -429.6 -383.1
Other Investing Cash Flow Items, Total -2167.7 -4832.8 544 -1598.2 -1079.9
Cash From Financing Activities -1009 -1005.8 -1970.5 -252.1 -77.1
Financing Cash Flow Items -445.7 -1032.7 -680.8 -188 -187.2
Issuance (Retirement) of Stock, Net -563.3 26.9 -3271.6 -64.1 110.1
Issuance (Retirement) of Debt, Net 0 0 1981.9 0
Net Change in Cash 221.3 690.8 577 150.1 655
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 817.8 4338.4 3141.3 1825.6 973.5
Cash From Operating Activities 1367.6 5014.9 3295 2666.1 2101.7
Cash From Operating Activities 99.5 341.4 241.3 148.7 74.3
Deferred Taxes -216.5 -746.4 -466.7 -381 -225
Non-Cash Items 425.9 1324.8 1004.4 1030.9 455.7
Changes in Working Capital 240.9 -243.3 -625.3 41.9 823.2
Cash From Investing Activities -235.7 -3784.6 -1926.9 -2119.2 -1705.3
Capital Expenditures -279.1 -1616.9 -1364.7 -295.4 -141.8
Other Investing Cash Flow Items, Total 43.4 -2167.7 -562.2 -1823.8 -1563.5
Cash From Financing Activities -322.5 -1009 -761.4 -36.4 64.7
Financing Cash Flow Items -97 -445.7 -256.6 -147.7 -98.8
Issuance (Retirement) of Stock, Net -225.5 -563.3 -504.8 111.3 163.5
Net Change in Cash 809.4 221.3 606.7 510.5 461.1
Issuance (Retirement) of Debt, Net 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Fidelity Management & Research Company LLC Investment Advisor 8.4629 9130793 -1527454 2023-03-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.1573 8801136 130059 2023-03-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.619 6062473 -94658 2023-03-31 LOW
Capital World Investors Investment Advisor 5.4041 5830586 -411849 2023-03-31 LOW
JP Morgan Asset Management Investment Advisor 4.5503 4909415 156161 2023-03-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.5357 4893616 -67269 2023-03-31 LOW
Dodge & Cox Investment Advisor/Hedge Fund 2.2103 2384701 161642 2023-03-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 2.0558 2217993 10003 2023-03-31 LOW
Capital International Investors Investment Advisor 1.9959 2153472 623529 2023-03-31 LOW
T. Rowe Price Associates, Inc. Investment Advisor 1.8837 2032374 449576 2023-03-31 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 1.6386 1767919 -648328 2023-03-31 LOW
Invesco Capital Management (QQQ Trust) Investment Advisor 1.3154 1419159 5544 2023-04-30 LOW
Loomis, Sayles & Company, L.P. Investment Advisor/Hedge Fund 1.2164 1312407 -25274 2023-03-31 LOW
Yancopoulos (George D) Individual Investor 1.133 1222370 -16824 2023-04-11 LOW
Putnam Investment Management, L.L.C. Investment Advisor/Hedge Fund 1.0801 1165317 47784 2023-03-31 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.8958 966467 -21169 2022-12-31 LOW
American Century Investment Management, Inc. Investment Advisor/Hedge Fund 0.8914 961710 -140292 2023-03-31 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.787 849127 17758 2023-03-31 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.7663 826791 129091 2023-03-31 LOW
BlackRock Asset Management Ireland Limited Investment Advisor 0.7598 819779 -39423 2023-03-31 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group

530K+

Traders

87K+

Active clients monthly

$46M+

Monthly investing volume

$31M+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Regeneron Company profile

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Industry: Bio Therapeutic Drugs

777 Old Saw Mill River Road
TARRYTOWN
NEW YORK 10591
US

Income Statement

  • Annual
  • Quarterly

People also watch

XRP/USD

0.47 Price
+0.030% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.00374

Gold

1,946.90 Price
+0.290% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0103%
Overnight fee time 21:00 (UTC)
Spread 0.60

Oil - Crude

72.94 Price
+1.570% 1D Chg, %
Long position overnight fee -0.0154%
Short position overnight fee -0.0065%
Overnight fee time 21:00 (UTC)
Spread 0.04

US100

14,326.80 Price
+2.750% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 3.0

Still looking for a broker you can trust?

Join the 530.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading